Applying Diagnostic Network Optimisation analysis to inform the introduction of G6PD testing into Indonesia for improved treatment of relapsing malaria

Background: Radical cure for P. vivax and P. ovale malaria using 8-aminoquinoline drugs primaquine or tafenoquine can prevent relapse, but requires glucose-6-phosphate dehydrogenase (G6PD) screening due to the risk of haemolysis in G6PD-deficient individuals. This study aimed to provide an evidence-based framework to inform the optimal allocation and referral networks for G6PD testing devices in Indonesia. Methods: A diagnostic network optimisation (DNO) analysis using OptiDx was conducted across eight districts in Sumba, North Sumatra, and Central Java, representing high-, moderate-, and low-

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.